https://www.selleckchem.com/pr....oducts/chloroquine-p
8, 95% CI, 0.61-1.06, P = .12). Almost half of the patients (45%) received a dose intensity 75%, 50%-75%, and less then 50% were 9.5 months, 12.9 months, and 7.1 months (P = .005) respectively. In multivariable models, starting dose(HR 1.16, 95% CI 0.93-1.44, P = .18 and mean dose intensity were not associated with survival. Conclusions Starting HCC patients on a reduced dose of sorafenib compared to full dose may not compromise survival. Mean dose-intensity of sorafenib may also not affect survival.The catalytic reducti
Beğen
Yorum Yap
Paylaş
